An Adjuvant Capsule in the Treatment of Pemphigus Vulgaris: A Novel Hypothesis

  • Farideh Jowkar Molecular Dermatology Research Center and Department of Dermatology, Shiraz University of Medical Sciences, Shiraz
  • Nasrin Saki Department of Dermatology, Shiraz university of medical sciences, Shiraz
  • Sina Kardeh Student research committee, Shiraz University of Medical Sciences, Shiraz
Keywords: Pemphigus Vulgaris, Adjuvant Therapy, Hypothesis

Abstract

Pemphigus vulgaris (PV) is one of the most common and studied autoimmune disorders of skin. The knock down of desmogleins in the skin by IgG antibodies will eventually leads to mucocutaneous problems in both genders. Targeting the cardinal molecules involved in the pathways of immune response is the main goal of given therapy. With regard to the side effects of long term use of immunosuppressive treatments, patients may use various adjuvant drug combinations. Sulfasalazine (SSZ) and Pentoxifylline (PTX) are two low-cost anti-TNF medications that can halt the acantholysis in PV. Tetracycline is an effective antibiotic with immunomdulatory properties on down-regulation of pro-inflammatory molecules such as NO, IL-1β. Moreover, the anti-inflammatory effects of Omega-3 take this supplement into account as a potential addition to anti-PV armamentarium. Thus, this complex could be utilized as a safe and effective adjuvant capsule against PV.

References

Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Jh[Wj_d] Pemphigus Vulgaris with Prednisone and MycophenolateMofetil: A Multicenter, Randomized, Placebo-Controlled Trial. J Invest Dermatol. 2010;130(8):2041-8.

Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003;149(5):926-37.

Prajapati V, Mydlarski PR. Advances in pemphigus therapy. Skin Therapy Lett. 2008;13: 4-7.

el-Darouti M, Marzouk S, Abdel Hay R, el-Tawdy A, Fawzy M, Leheta T, et al. The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study. Br J Dermatol. 2009;161(2):313-9.

Tauber SC, Nau R. Immunomodulatory Properties of Antibiotics. CurMolPharm. 2008;1(1):68-79.

Calebotta A, Sáenz AM, González F, Carvalho M, Castillo R. Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients. Int J Dermatol. 1999;38(3):217-21.

Ozog DM, Gogstetter DS, Scott G, Gaspari AA. Minocycline induced hyperpigmentation in patients with pemphigus and pemphigoid. Arch Dermatol. 2000;136(9):1133-8.

Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am CollNutr. 2002;21(6):495-505.

Published
2014-08-31
How to Cite
Jowkar, F., Saki, N., & Kardeh, S. (2014). An Adjuvant Capsule in the Treatment of Pemphigus Vulgaris: A Novel Hypothesis. Galen Medical Journal, 3(3), 200-1. Retrieved from https://gmj.ir/index.php/gmj/article/view/263
Section
Medical Idea